Stock listing

NASDAQ:LFWD Lifeward Ltd. Stock

Home listing (NASDAQ) of Lifeward Ltd.

Follow Lifeward Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:LFWD

$2.80 USD -0.40 (-12.4%)

Close on Nov 20, 2026

Past year -55.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.73 – $2.98 USDNov 20, 2026
Volume
35,411 sharesNov 20, 2026
Market cap
$7.94M USDAt the close on Nov 20, 2026 · price × 2.83M shares outstanding
52-week range
$2.73 – $9.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$68,807 USDMedian day 5,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lifeward Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LFWD · Home$2.803 USD-0.397 (-12.4%)35,411$2.80$2.98$2.73$3.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LFWD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.803-0.397-12.4%$2.80$2.98$2.7335,411
$3.20+0.10+3.2%$3.08$3.40$3.0413,371
$3.10-0.52-14.4%$3.46$3.52$3.1032,433
$3.62-0.44-10.8%$4.03$4.17$3.3931,679
$4.06-1.66-29.0%$5.42$5.42$3.8130,400
$5.72-0.04-0.7%$5.71$5.77$5.545,500
$5.76-0.085-1.5%$5.84$5.969$5.755,900
$5.845-0.095-1.6%$5.88$5.955$5.806,600
$5.94+0.13+2.2%$5.97$6.18$5.912,100
$5.81+0.07+1.2%$5.65$5.964$5.655,000
$5.74-0.32-5.3%$5.97$6.10$5.7455,400
$6.06+0.23+3.9%$6.05$6.17$5.9822,900
$5.83-0.23-3.8%$6.02$6.16$5.8249,600
$6.06+0.108+1.8%$5.95$6.29$5.92594,500
$5.952+0.042+0.7%$5.87$6.10$5.873,500
$5.91+0.16+2.8%$5.91$5.91$5.911,100
$5.75-0.29-4.8%$5.80$6.15$5.7522,800
$6.04+0.23+4.0%$5.98$6.26$5.8512,800
$5.81-0.25-4.1%$6.10$6.10$5.818,500
$6.06+0.243+4.2%$5.64$6.06$5.6423,200
$5.817+0.317+5.8%$5.566$5.93$5.4684,000
$5.50-0.11-2.0%$5.52$5.61$5.454,300
$5.61-0.32-5.4%$5.80$5.80$5.611,800
$5.93-0.07-1.2%$6.16$6.20$5.886,400
$6.00-0.06-1.0%$6.13$6.53$6.0023,900
$6.06-0.16-2.6%$6.07$6.07$6.061,200
$6.22+0.12+2.0%$6.15$6.25$6.15800
$6.10-0.12-1.9%$6.102$6.17$6.0510,200
$6.22-0.27-4.2%$6.446$6.461$6.221,700
$6.49+0.06+0.9%$6.30$6.61$6.103,700
$6.43-0.07-1.1%$6.30$6.50$6.105,000
$6.50+0.16+2.5%$6.10$6.50$6.102,900
$6.34-0.33-4.9%$6.66$6.80$6.1010,000
$6.67+0.82+14.0%$6.04$6.70$6.0410,400
$5.85-0.11-1.8%$5.903$6.35$5.856,100
$5.96-0.641-9.7%$5.43$6.48$5.1811,900
$6.601-0.309-4.5%$6.91$6.91$6.5524,500
$6.91-0.01-0.1%$6.92$6.92$6.911,000
$6.92-0.07-1.0%$7.00$7.00$6.926,000
$6.99+0.02+0.3%$6.94$6.99$6.94900
$6.97-0.04-0.6%$7.10$7.114$6.957,900
$7.01+0.07+1.0%$7.00$7.01$6.956,400
$6.94-0.06-0.9%$6.90$7.18$6.902,000
$7.00+0.08+1.2%$7.16$7.16$6.752,100
$6.92-0.04-0.6%$7.10$7.20$6.925,300
$6.96+0.05+0.7%$6.92$7.19$6.906,600
$6.91-0.16-2.3%$7.322$7.322$6.915,000
$7.07-0.04-0.6%$7.35$7.35$7.017,100
$7.11-0.01-0.1%$7.254$7.254$6.86910,300
$7.12-0.01-0.1%$7.39$7.39$7.12900
$7.13-0.27-3.6%$7.12$7.15$7.122,400
$7.400.000.0%$7.40$7.40$7.40389
$7.40+0.42+6.0%$6.99$7.40$6.994,300
$6.98-0.12-1.7%$7.105$7.105$6.987,600
$7.10-0.16-2.2%$7.27$7.332$7.034,200
$7.26+0.06+0.8%$7.21$7.26$7.103,500
$7.20-0.45-5.9%$7.53$7.575$7.205,600
$7.65+0.19+2.5%$7.47$7.683$7.415,400
$7.46+0.095+1.3%$7.30$7.50$7.204,400
$7.365-0.125-1.7%$7.535$7.67$7.3655,300
$7.49+0.10+1.4%$7.30$7.49$7.302,500
$7.39+0.10+1.4%$7.39$7.54$7.2823,800
$7.29-0.03-0.4%$7.415$7.475$7.109,500
$7.32-0.01-0.1%$7.41$7.505$7.328,900
$7.33+0.06+0.8%$7.36$7.37$7.196,000

Splits

3 splits since 2019 · NASDAQ:LFWD · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-7Consolidation
1-for-25Consolidation
Ticker
NASDAQ:LFWD
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lifeward Ltd. news

Lifeward Ltd. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
25 in the last 12 months · 179 in all · newest Nov 13, 2026 · oldest 2019
Calls
10 calls with a replay · 10 with a transcript · latest May 15, 2026
Decks
7 decks · latest September 2026

Where Lifeward Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:LFWD · Home listing · This pageNASDAQUnited StatesUSD
gettex:2RWgettexGermanyEUR
LS Exchange:A12BMBLS ExchangeGermanyEUR
BOATS:LFWDBOATSUnited StatesUSD
Lang & Schwarz:A12BMBLang & SchwarzGermanyEUR
Munich:2RWMunichGermanyEUR

Valuation

EV/sales 0.3× against a median of 15.1×: 3rd lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.86M USD
P/E
Loss
EV/sales
0.3×
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
31.5%
Operating margin
−121.5%
Net margin
−155.4%
Debt to equity
0.3×
Beta vs S&P 500
1.22

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lifeward Ltd. · NASDAQ:LFWDUS$7.94MUS$5.86Mn/a0.3×n/a1.1×−155.4%0.3×1.22
VVT Med Inc. · TSXV:VVTMUS$8.99MUS$8.99Mn/a93.6×n/an/an/an/a1.16
SpineGuard · EURONEXT:ALSGDUS$8.88MUS$9.65Mn/a2.3×n/a1.8×−55.0%0.3×n/a
Pulsenmore Ltd. · TASE:PLSMUS$8.71MUS$2.27Mn/a0.2×n/a0.3×−39.6%0.0×n/a
Conavi Medical Corp. · TSXV:CNVIUS$8.66MUS$8.89Mn/a15.1×n/an/an/an/a0.36
Allmed Solutions Ltd. · TASE:ALMDUS$8.42MUS$1.41Mn/an/an/a1.4×n/a0.0×n/a
ReNerve Limited · ASX:RNVUS$8.04MUS$7.05Mn/a20.9×n/a3.8×n/a0.0×n/a
IRIDEX Corporation · NASDAQ:IRIXUS$7.92MUS$11.69Mn/a0.2×n/a3.0×−6.9%2.8×0.90
Clinical Laserthermia Systems AB Class B · OMXSTO:CLS_BUS$7.54MUS$7.16Mn/a5.8×n/a1.6×−314.6%0.0×n/a
BioElectronics Corp. · OTC:BIELUS$7.41MUS$23.70Mn/a46.4×n/an/a−104.3%n/a2.45
Airway Medix SA · GPW:AWMUS$6.73MUS$10.07Mn/a278×n/an/an/an/an/a
Median of the othersUS$8.23MUS$8.94M15.1×1.7×−55.0%0.0×1.03

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
20.00 USD · Analysts' mean
EPS, year to Dec 2026
-5.02 · 1 analyst
Revenue, year to Dec 2026
25.24M · 2 analysts

Team and board

Officers

OfficerRole
Josh HexterChief Executive Officer
Ronan TsimermanChief Financial Officer
Craig PetersVice President of Sales
David HexnerVice President of Research and Development
Miri ParienteVice President of Operations, Regulatory and Quality
Ami KraftExecutive Advisor to the CEO
Keith D. RoseChief Medical Officer
Mela IkanovicDeputy General Manager and Vice President of International Sales

Board

DirectorRole
Bob MarshallChairman of the Board

Events

Calls

CallWhenStatus
Lifeward (NASDAQ:LFWD) Q1 2026 Earnings CallFri, May 15, 2026 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q4 2025 Earnings CallWed, Mar 18, 2026 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q3 2025 Earnings CallFri, Nov 14, 2025 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q2 2025 Earnings CallThu, Aug 14, 2025 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q1 2025 Earnings CallThu, May 15, 2025 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q4 2024 Earnings CallFri, Mar 07, 2025 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q2 2024 Earnings CallThu, Aug 15, 2024 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q1 2024 Earnings CallWed, May 15, 2024 · 8:30 AM ETReplay
Lifeward (NASDAQ:LFWD) Q4 2023 Earnings CallTue, Feb 27, 2024 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open−29.0%
Q2 2026Aug 14, 2026 · Before open−5.6%
Q1 2026May 15, 2026 · Before open+1.6%
Q4 2025Mar 18, 2026 · Before open−11.1%
Q3 2025Nov 14, 2025 · Before open+14.8%
Q2 2025Aug 14, 2025 · Before open−14.6%
Q1 2025May 15, 2025 · Before open−10.4%
Q4 2024Feb 25, 2025 · Before open−0.6%
Q3 2024Nov 12, 2024 · Before open+0.8%
Q2 2024Aug 14, 2024 · After close+30.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open−2.7%
Q4 2023Feb 27, 2024 · Before open+0.3%
Q3 2023Nov 14, 2023 · Before open+2.4%
Q2 2023Aug 11, 2023 · Before open−1.8%
Q1 2023May 11, 2023 · Before open+1.0%
Q4 2022Feb 23, 2023 · Before open−3.0%
Q3 2022Nov 7, 2022 · Before open−2.8%
Q2 2022Aug 9, 2022 · Before open0.0%
Q1 2022May 13, 2022 · After close−2.3%
Q4 2021Feb 24, 2022 · Before open−1.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck17 slidesSeptember 2026
ReWalk Robotics — Investor Presentation (April 2024)Investor deck26 slidesApr 3, 2024
ReWalk Robotics — Investor Presentation (October 2023)Investor deck32 slidesOct 13, 2023
ReWalk Robotics — Merger or Acquisition (August 2023)Merger or acquisition11 slidesAug 9, 2023
ReWalk Robotics — Investor Presentation (April 2023)Investor deck31 slidesApr 28, 2023
ReWalk Robotics — IPO Roadshow (January 2020)IPO roadshow28 slidesJan 30, 2020
ReWalk Robotics — Investor Presentation (November 2018)Investor deck22 slidesNov 13, 2018

Open Decks

Financings

RaiseDate
Senior secured convertible notes and accompanying warrants
Tranche closed: US$5.6M raised
Use of proceeds: Accelerate commercialization of its restorative healthcare platform, expand its reimbursement-backed distribution model and advance its product portfolio
Jul 7, 2026
Strategic investment of ordinary shares, prefunded warrants, convertible notes and warrants
Announced: up to US$47M · additional warrants to acquire up to $7 million in ordinary shares of Lifeward
Buyers: Oramed (up to a 49.99% equity ownership in Lifeward)
Use of proceeds: Cash runway to profitability and selective investment in high-value innovation
Jan 13, 2026
Public offering of ordinary shares and accompanying warrants
Closed: US$2.6M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Continuing commercial efforts, working capital and general corporate purposes
Jun 26, 2025
Registered direct offering of ordinary shares and unregistered warrants
Announced: about US$5M · US$2.75 a share · Warrants at US$2.75 for 36 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Continuing commercial efforts, working capital and general corporate purposes
Jan 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as ReWalk Robotics Ltd. Priced at US$12.00 a share on Sep 11, 2014.

Price
US$12.00 a share
Shares offered
3,000,000 ordinary shares
Offering size
US$36 million
Underwriters' option
Up to 450,000 more shares
Underwriters
Barclays, Jefferies, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Sep 17, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceMay 16, 2014
Filed publiclyJul 10, 2014
Amended 3 timesNewest Aug 26, 2014
Shares registered with an exchangeSep 2, 2014
Declared effective by the SECSep 11, 2014
Final prospectus, with the priceSep 15, 2014

Open IPO · From the cover of the final prospectus (424B1) filed Sep 15, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue22.0M25.7M13.9M5.51M5.97M4.39M
Cost of revenue13.6M17.4M9.40M3.61M3.06M2.20M
Gross profit8.43M8.22M4.45M1.91M2.90M2.19M
Research and development3.25M4.63M4.15M4.03M2.94M3.46M
Selling, general and administrative8.20M5.20M9.99M7.13M5.63M4.98M
Operating income-19.7M-29.3M-23.6M-19.1M-12.7M-12.0M
Depreciation and amortization333.0K494.0K239.0K202.0K266.0K285.0K
EBITDA-19.3M-28.9M-23.4M-18.9M-12.4M-11.7M
Interest expense295.0K128.0K20.0K22.0K0907.0K
Income before tax-20.0M-28.9M-22.1M-19.1M-12.6M-12.9M
Income tax-55.0K43.0K-12.0K467.0K94.0K51.0K
Net income-19.9M-28.9M-22.1M-19.6M-12.7M-13.0M
Earnings per share, basic-17.16-39.96-31.13-2.20-0.27-0.82
Earnings per share, diluted-17.16-39.96-31.13-2.20-0.27-0.82

Balance sheet

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Cash and equivalents2.17M6.75M28.1M28.1M67.9M67.9M88.3M88.3M20.4M20.4M
Receivables6.14M6.00M3.12M3.12M1.04M1.04M585.0K585.0K684.0K684.0K
Inventory5.73M6.72M5.65M5.65M2.93M2.93M2.99M2.99M3.54M3.54M
Current assets15.8M21.3M39.2M39.2M72.5M72.5M92.5M92.5M25.2M25.2M
Property, plant and equipment585.0K867.0K1.26M196.0K284.0K437.0K
Goodwill4.75M7.54M7.54M7.54M0
Total assets22.9M30.5M63.2M63.2M74.2M74.2M94.8M94.8M28.1M28.1M
Accounts payable5.59M5.02M5.07M5.07M1.95M1.95M1.38M1.38M2.27M2.27M
Current liabilities12.0M10.2M11.8M11.8M4.78M4.78M4.04M4.04M4.67M4.67M
Total debt4.39M880.0K1.90M1.90M897.0K897.0K1.06M1.06M1.58M1.58M
Total liabilities14.5M11.6M16.7M16.7M6.07M6.07M5.37M5.37M6.29M6.29M
Shareholders' equity8.41M18.8M46.5M46.5M68.2M68.2M89.4M89.4M21.8M21.8M
Shares outstanding1.52M734.0K8.59M60.1M62.5M25.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-16.8M-21.7M-20.7M-17.9M-11.5M-12.6M
Capital spending-16.0K0-81.0K-25.0K-47.0K-73.0K
Free cash flow-16.8M-21.7M-20.7M-17.9M-11.5M-12.7M
Cash from investing-16.0K0-18.1M-25.0K-47.0K-73.0K
Cash from financing12.2M0-992.0K-2.50M79.5M16.7M
Share buybacks00-992.0K-2.50M0
Change in cash-4.53M-21.7M-39.8M-20.5M68.0M4.06M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
8-K · Current reportNov 5, 2026Meeting outcomeSEC
3 · Initial statement of ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportOct 27, 2026Management or board changeSEC
8-K · Current reportOct 8, 2026Management or board changeSEC
8-K · Current reportOct 1, 2026Management or board changeSEC
ARS · Annual report to shareholdersSep 25, 2026Annual reportSEC
DEF 14A · Proxy statementSep 25, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementSep 15, 2026Meeting noticeSEC
8-K · Current reportSep 15, 2026Current reportSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Current reportSEC
3 · Initial statement of ownershipSep 1, 2026Insider tradeSEC
8-K · Current reportAug 31, 2026Management or board changeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 24, 2026Insider tradeSEC
8-K · Current reportAug 20, 2026Management or board changeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveAug 11, 2026Other filingsSEC
S-3 · Registration statementAug 3, 2026Offer documentSEC
DJul 8, 2026Other filingsSEC
8-K · Current reportJul 7, 2026Material contractSEC
SD · Specialized disclosureMay 29, 2026ESG reportSEC
S-8 · Registration statement for employee plansMay 20, 2026Offer documentSEC
10-Q · Quarterly reportMay 20, 2026Quarterly reportSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Current reportSEC
NT 10-Q · Late filing noticeMay 15, 2026Explanation requestSEC
8-K · Current reportMay 15, 2026ResultsSEC
3 · Initial statement of ownershipMay 14, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeMay 14, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 13, 2026Other filingsSEC
CORRESP · Letter to the SECMay 8, 2026Other filingsSEC
DEL AMMay 8, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 1, 2026Other filingsSEC
S-3 · Registration statementApr 27, 2026Offer documentSEC
8-K · Current reportApr 23, 2026Management or board changeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
DApr 2, 2026Other filingsSEC
8-K · Current reportMar 31, 2026Current reportSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
8-K · Current reportMar 25, 2026Acquisition or disposalSEC
8-K · Current reportMar 20, 2026Current reportSEC
10-K · Annual reportMar 18, 2026Annual reportSEC
8-K · Current reportMar 18, 2026ResultsSEC
8-K · Current reportMar 13, 2026Meeting outcomeSEC
8-K · Current reportMar 11, 2026Current reportSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 27, 2026Management or board changeSEC
8-K · Current reportFeb 25, 2026FinancingSEC
8-K · Current reportFeb 19, 2026Material contractSEC
DEFM14AFeb 9, 2026Meeting noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
PREM14AJan 28, 2026Other filingsSEC
8-K · Current reportJan 28, 2026Management or board changeSEC
8-K · Current reportJan 13, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveJan 7, 2026Other filingsSEC
8-K · Current reportJan 6, 2026Meeting outcomeSEC
CORRESP · Letter to the SECJan 2, 2026Other filingsSEC
S-3/A · Registration statement, amendedJan 2, 2026Offer documentSEC
8-K · Current reportDec 19, 2025Management or board changeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
DEF 14A · Proxy statementDec 1, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 21, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
8-K · Current reportOct 16, 2025ResultsSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
S-8 POSAug 25, 2025Offer documentSEC
S-8 POSAug 25, 2025Offer documentSEC
S-8 POSAug 25, 2025Offer documentSEC
S-8 POSAug 25, 2025Offer documentSEC
S-8 POSAug 25, 2025Offer documentSEC
S-8 · Registration statement for employee plansAug 25, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
8-K · Current reportAug 13, 2025Management or board changeSEC
8-K · Current reportAug 8, 2025Current reportSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
8-K · Current reportAug 5, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJul 1, 2025Big-stake noticeSEC
8-K · Current reportJun 26, 2025Material contractSEC
DEF 14A · Proxy statementJun 26, 2025Meeting noticeSEC
424B4 · ProspectusJun 26, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 26, 2025Other filingsSEC
S-1/A · Registration statement, amendedJun 25, 2025Offer documentSEC
CORRESP · Letter to the SECJun 23, 2025Other filingsSEC
CORRESP · Letter to the SECJun 23, 2025Other filingsSEC
S-1 · Registration statementJun 20, 2025Offer documentSEC
8-K · Current reportJun 16, 2025Management or board changeSEC
PRE 14A · Preliminary proxy statementJun 16, 2025Meeting noticeSEC
CORRESP · Letter to the SECJun 10, 2025Other filingsSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportJun 3, 2025Management or board changeSEC
SD · Specialized disclosureMay 28, 2025ESG reportSEC
DRS · Draft registration statementMay 27, 2025Offer documentSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
UPLOAD · Letter from the SECMay 21, 2025Other filingsSEC
8-K · Current reportMay 19, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
S-3 · Registration statementMay 15, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportApr 15, 2025Current reportSEC
8-K · Current reportApr 14, 2025ResultsSEC
8-K · Current reportMar 7, 2025Material contractSEC
424B5 · ProspectusMar 7, 2025Offer documentSEC
10-K · Annual reportMar 7, 2025Annual reportSEC
8-K · Current reportMar 7, 2025ResultsSEC
8-K · Current reportFeb 20, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 14, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 14, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 13, 2025Other filingsSEC
S-1 · Registration statementFeb 11, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 14, 2025Big-stake noticeSEC
DJan 13, 2025Other filingsSEC
8-K · Current reportJan 13, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2025Big-stake noticeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
8-K/A · Current report, amendedJan 8, 2025Current reportSEC
8-K · Current reportJan 8, 2025Material contractSEC
424B5 · ProspectusJan 8, 2025Offer documentSEC
DEFA14A · Additional proxy materialDec 27, 2024Meeting noticeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
DEF 14A · Proxy statementNov 25, 2024Meeting noticeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementNov 15, 2024Meeting noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
3 · Initial statement of ownershipNov 7, 2024Insider tradeSEC
8-K · Current reportNov 7, 2024Management or board changeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
8-K · Current reportSep 4, 2024Management or board changeSEC
DEFA14A · Additional proxy materialAug 26, 2024Meeting noticeSEC
8-K · Current reportAug 15, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialAug 9, 2024Meeting noticeSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
144 · Notice of proposed saleAug 5, 2024Other filingsSEC
DEF 14A · Proxy statementJul 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 19, 2024Meeting noticeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
8-K · Current reportJul 2, 2024Management or board changeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
SD · Specialized disclosureMay 28, 2024ESG reportSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
4 · Change in ownershipApr 22, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 22, 2024Insider tradeSEC
8-K · Current reportApr 19, 2024Management or board changeSEC
8-K · Current reportApr 4, 2024Current reportSEC
8-K · Current reportApr 3, 2024Current reportSEC
10-K · Annual reportFeb 27, 2024Annual reportSEC
8-K · Current reportFeb 27, 2024ResultsSEC
8-K · Current reportJan 30, 2024Current reportSEC
8-K · Current reportDec 19, 2023Current reportSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
144 · Notice of proposed saleNov 20, 2023Other filingsSEC
144 · Notice of proposed saleNov 17, 2023Other filingsSEC
4 · Change in ownershipNov 16, 2023Insider tradeSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K/A · Current report, amendedOct 27, 2023Current reportSEC
8-K · Current reportOct 13, 2023Current reportSEC

This page holds 200 of 866 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lifeward Ltd.’s releases · as of Jul 7, 2026

Common shares
2,832,016
Fully diluted
2,832,016

Fully diluted

LineShares
Common shares2,832,016

Warrants and options

Lot
Warrants · US$0.65 · expire about Jun 2030

Share count over time

CountShares
Nov 22, 20262,832,016

Open Cap table

Shareholders

HolderSharesValueAs of
Dimensional US Core Equity 1 ETF804US$5,716Jul 31, 2026
Fidelity Nasdaq Composite Index Fund216US$1,715May 31, 2026
Dimensional U.S. Core Equity 2 ETF97US$690Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Glenn P. Muir
Other companies: Cytek Biosciences, Inc. (Director · Since at least Jun 10, 2026); Neuronetics, Inc. (Board Member · Since at least Jun 27, 2018); Repligen Corporation (Director · Since at least Sep 14, 2015); G1 Therapeutics Inc (Director · May 16, 2017 – Sep 18, 2024 · Past); Hologic Inc (Executive VP and CFO · Feb 1, 2006 – May 8, 2014 · Past)
Director · Dec 31, 2015 – Jun 27, 2017 · Past
Nadav Kidron
Other companies: Nano Dimension Ltd (Director · Since at least Aug 16, 2026); Alpha Tau Medical Ltd (Director · Since at least May 12, 2025); Oramed Pharmaceuticals Inc. (President and CEO, Director · Since at least Feb 3, 2006)
Director · Since at least Mar 25, 2026
Avraham Gabay
Other companies: Oramed Pharmaceuticals Inc. (Chief Financial Officer · Since at least Jun 18, 2024); BiomX Inc. (Interim CFO · Dec 6, 2023 – Dec 6, 2023 · Past)
Director · Since at least Aug 20, 2026
Hadar Levy
Other companies: BrainsWay Ltd (Chief Executive Officer (CEO) · Since at least Mar 18, 2026)
Director · Since at least Aug 1, 2025
Lawrence Jasinski
Other companies: LeMaitre Vascular, Inc. (Board Director · Since at least Jul 26, 2010)
Chief Executive Officer, Director · Dec 31, 2015 – May 21, 2025 · Past
Michael Lawless
Other companies: InspireMD Inc. (CFO · Since at least Jun 25, 2025)
Chief Financial Officer · Sep 19, 2022 – May 23, 2024 · Past
Miriam Kidron
Other companies: Oramed Pharmaceuticals Inc. (Chief Scientific Officer, Director · Since at least Dec 31, 2025)
Director · Since at least Mar 25, 2026
Moshe Rozenbaum
Other companies: Nano Dimension Ltd (Interim CEO · Since at least Oct 26, 2026)
Director · Since at least Mar 25, 2026
Robert J Marshall Jr
Other companies: Lantheus Holdings, Inc. (CFO and Treasurer · Since at least Jun 9, 2025)
Director · Since at least Aug 1, 2025
Yehuda Reznick
Other companies: Oramed Pharmaceuticals Inc. (Director · Since at least Apr 1, 2024)
Director · Since at least Mar 25, 2026
All 30 people
PersonSeat
Almog AdarChief Financial Officer · Since at least Mar 12, 2022
Ami KraftExecutive Advisor to the CEO · Since at least Nov 5, 2026
Bob MarshallChairman of the Board · Since at least Dec 19, 2025
Charles RemsbergChief Sales Officer · Aug 11, 2023 – Aug 11, 2023 · Past
Chunlin HanDirector · May 15, 2019 – May 15, 2019 · Past
Craig PetersVice President of Sales · Since at least Nov 5, 2026
David HexnerVice President of Research and Development · Since at least Feb 25, 2026
Haggai ZamirDirector · Since at least Aug 14, 2026
Jeannine LynchVP of Market Access & Strategy · Since at least Aug 31, 2021
John Vincent HamiltonVP, Regulatory and Clinical · Jan 13, 2016 – Jul 25, 2016 · Past
Joseph E Turk JrDirector · Since at least Apr 20, 2022
Josh HexterChief Executive Officer · Since at least Oct 14, 2026
Keith D. RoseChief Medical Officer · Since at least May 1, 2026
Mela IkanovicDeputy General Manager and Vice President of International Sales · Since at least Nov 5, 2026
Miri ParienteVice President of Operations, Regulatory and Quality · Since at least Nov 5, 2026
Randel RichnerDirector · Since at least Nov 1, 2020
Ronan TsimermanChief Financial Officer · Since at least Nov 5, 2026
William Mark GrantPresident & CEO, Director · Since at least Jun 2, 2025
William Mark SigsbeeDirector · Since at least Mar 25, 2026
Yonason GreenwaldDirector · Since at least Aug 14, 2026

Open People

Log in to ask 6ix AI your own questions about Lifeward Ltd.